Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.
Press releases published on September 11, 2025
InnovAge Named as One of the Nation’s Best Workplaces in Aging Services™ by Fortune® and Great Place to Work®
DENVER, Sept. 11, 2025 (GLOBE NEWSWIRE) -- InnovAge (NASDAQ: INNV), a leading provider of Program of All-Inclusive Care for the Elderly (PACE), has been named to the Fortune Best Workplaces in Aging Services ranking among the top 15 organizations in the …
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025
Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
Acentra Health CEO Todd Stottlemyer Named by Virginia Business to its ‘Virginia 500 Power List’ for Fourth Consecutive Year
MCLEAN, Va., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, today …
Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance
RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal …
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy …
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the …
Mass General Brigham’s Kraft Center Announces Winner and Finalists of the 2025 Kraft Prize for Excellence and Innovation in Community Health
Boston, MA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inaugural $100k award goes to St. Louis company making a transformative impact in its community Organizations supporting maternal health and substance use disorder recognized as finalists Boston, MA – Today, …
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage …
Rare Kidney Disease Community Members Join American Kidney Fund and IgA Nephropathy Foundation on Capitol Hill to Champion Key Legislation
ROCKVILLE, Md., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation, joined by more than 50 advocates living with rare kidney diseases, are convening on Capitol Hill to rally support for policy …
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persistent drug-related adverse events Results were leveraged to design confirmatory trial planned for 2026 FORT …
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its …
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting- …
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available treatments for IPF are limited to only two approved drugs …
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four …
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug- …
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: …
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE …
Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for …